These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 11764539

  • 41. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA.
    J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
    [Abstract] [Full Text] [Related]

  • 42. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
    Tuynman JB, Hulscher JB, Steller EP, van Lanschot JJ, Richel DJ.
    Ned Tijdschr Geneeskd; 2003 Nov 08; 147(45):2207-12. PubMed ID: 14640057
    [Abstract] [Full Text] [Related]

  • 43. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG.
    Health News; 2002 Aug 08; 8(8):5. PubMed ID: 12206146
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [The use of non-steroidal anti inflammatory drugs (NSAIDs)--COX-2 inhibitors].
    Tishler M, Langevetiz P, Nesher G.
    Harefuah; 2002 Oct 08; 141(10):920-1. PubMed ID: 12420601
    [No Abstract] [Full Text] [Related]

  • 46. Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?
    Simon LS.
    Curr Opin Rheumatol; 2000 May 08; 12(3):163-70. PubMed ID: 10803743
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [COX-2 inhibitor to whom?].
    Martio J.
    Duodecim; 2000 May 08; 116(12):1265-7. PubMed ID: 11988961
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. COX-2: a molecular target for colorectal cancer prevention.
    Brown JR, DuBois RN.
    J Clin Oncol; 2005 Apr 20; 23(12):2840-55. PubMed ID: 15837998
    [Abstract] [Full Text] [Related]

  • 54. Introduction. The role of COX-2-specific inhibitors in clinical practice.
    Lipsky PE.
    Am J Med; 2001 Feb 19; 110 Suppl 3A():1S-2S. PubMed ID: 11173042
    [No Abstract] [Full Text] [Related]

  • 55. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA.
    Semin Urol Oncol; 2001 Nov 19; 19(4):294-305. PubMed ID: 11769881
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. COX-2-selective inhibition: a new advance in pain management. Chairman's introduction.
    Korttila K.
    Eur J Anaesthesiol Suppl; 2002 Nov 19; 25():1-2. PubMed ID: 12449671
    [No Abstract] [Full Text] [Related]

  • 59. [Cyclooxygenase 2 inhibitors and lung carcinoma].
    Spano JP, Chouahnia K, Morère JF.
    Bull Cancer; 2004 May 19; 91 Spec No():S109-12. PubMed ID: 15239338
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.